Atosiban Acetate Salt API CAS 90779-69-4 | Peptide Manufacturer
Atosiban Acetate Salt API CAS 90779-69-4 | Peptide Manufacturer
Atosiban Acetate API,CAS 90779-69-4,Atosiban Acetate,Custom Peptide Synthesis,Bulk Peptide Supplier,oxytocin receptor antagonist,tocolytic raw material,cGMP Peptide Manufacturing
Source high-purity Atosiban Acetate peptide API (CAS 90779-69-4) directly from cGMP manufacturer. Purity ≥98.0% by HPLC. Flexible packaging from mg to bulk kg for obstetric formulation R&D.
Send Inquiry
Description
cGMP STANDARD PHARMACEUTICAL PEPTIDE SUPPLIER
Atosiban Acetate Salt
CAS No.: 90779-69-4
Purity (HPLC)≥ 98.0%
Molecular FormulaC43H67N11O12S2·xC2H4O2
Molecular Weight~1054.30 (acetate salt)
Peptide Content / AcetateCustom / Controlled
💡 Quick Connection Notice: If your email link doesn't open, please directly send inquiries to: betty@pharma-sunrise.com
Scientific Overview & High-Quality Custom Peptide Synthesis
We specialize in the contract manufacturing and high-capacity market supply of premium Atosiban Acetate API, a complex synthetic nonapeptide. Processed under advanced solid-phase peptide synthesis (SPPS) workflows and verified by comprehensive cGMP quality systems, this raw material maintains an exceptional analytical purity of ≥98% via HPLC methodology with outstanding structural and batch-to-batch consistency.
Our standardized quality frameworks minimize chemical variations, supporting global formulation developers through the entire pipeline—spanning from pre-clinical laboratory research and generic drug development up to commercial-scale API scaling and manufacturing. We offer versatile packaging structures covering milligram-level trial samples up to bulk kilogram lots.
Pharmacological Profile & API Formulation Targets
Mechanism of Action (MoA)
Atosiban functions as a highly potent, competitive receptor antagonist. It specifically binds to oxytocin receptors and vasopressin V1a receptors distributed across human uterine myometrium and decidua tissues. By displacing endogenous oxytocin from binding targets, it cuts off downstream calcium signaling transduction, lowering intracellular calcium thresholds and effectively halting smooth muscle contraction at the source.
Clinical Formulation Benchmarks
When formulated into finished injectable preparations, this API targets the rapid inhibition of uterine hypercontractility with superior clinical safety and tolerance compared to non-selective tocolytics. Formulations are indicated to stabilize patients between 24 and 33 weeks of gestation presenting imminent preterm labor, buying critical time for antenatal corticosteroid delivery or hospital cold chain referral.
Pharmaceutical Applications & Research Scenarios
Pharmaceutical Production: Serves as the key raw material for approved generic tocolytic injectables.
Pharmaceutical R&D: Widely adopted as a reference standard in obstetric and gynecological studies, preterm birth pathogenesis research, and the exploration of novel non-invasive peptide delivery systems.
Technical Specifications & Cold Chain Logistics Standard
| Product Identity | Atosiban Acetate (Synthetic Polypeptide API) |
|---|---|
| Physical Characteristics | White to off-white lyophilized crystalline powder |
| Testing Method & Purity | HPLC Analysis; Assay ≥ 98.0% |
| Flexible Packaging Matrix | • R&D Scale: 10mg – 100mg per sterile glass vial • Pilot Tiers: 1g – 5kg per advanced aluminum vacuum foil bag • Commercial T Bulk: 25kg inside heavy-duty fiber drums *Fully customizable packaging configurations are available upon request. |
| Storage & Cold Chain Mandates | Store in a tightly sealed container at sub-zero conditions -20°C ± 5°C. Protect strictly from light and moisture ingress to prevent peptide chain degradation. Avoid repeated freeze-thaw cycles. |
| Shelf Life Reference | 36 months under the proper recommended sealed and low-temperature storage conditions. |
Frequently Asked Questions (Peptide Procurement)
Can you guarantee the peptide purity and provide corresponding batch testing data?
Yes. Our Atosiban Acetate API undergoes stringent quality control testing and solid-phase synthesis monitoring. We provide a complete Certificate of Analysis (COA) with every batch, backed by comprehensive HPLC chromatograms ensuring a minimum purity of ≥98.0%, alongside Mass Spectrometry (MS) data to confirm the exact structural identity and molecular weight.
Do you accommodate custom packaging sizes for laboratory scale R&D?
Absolutely. We fully support custom peptide synthesis pipelines. Beyond our commercial 1kg to 5kg foil vacuum units, we support formulation researchers with exact milligram or customized container volumes (10mg - 100mg) to minimize raw material waste during developmental scaling.
How is the -20°C storage requirement managed during international shipping?
To ensure the complete molecular integrity of the lyophilized peptide powder, we deploy specialized cold-chain logistics for all international air freight. The API is securely vacuum-sealed in moisture-proof aluminum foil and shipped utilizing validated temperature-controlled containers equipped with integrated temperature data loggers.
Is this API available for direct clinical injection or patient prescription?
No. As clearly stated in our declaration, this product is an active pharmaceutical ingredient (API) and research chemical intended strictly for professional laboratory research and B2B finished drug manufacturing. It cannot be used directly for human clinical medication or direct patient injection.
Shaanxi Sunrise Pharmaceutical Co., Ltd.
Senior Independent Site Operations Specialist: Betty
📧 Email: betty@pharma-sunrise.com|💬 WhatsApp: +86 18092760627